ENP110: Hypercortisolism and T2D

About this episode

This episode discusses the relationship between hypercortisolism and type 2 diabetes with expert guests.

For some people, diabetes can be very hard to control, even with the standard glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. What’s the relationship between type 2 diabetes and hypercortisolism, and what do health care providers need to know about that relationship? To help answer those questions, host Aaron Lohr talks with two guests. Vivian A. Fonseca, MD , is a professor of medicine, assistant dean for clinical research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the section of endocrinology at Tulane University Medical Center in New Orleans. James W. Findling, MD , is a professor of medicine and surgery at the Medical College of Wisconsin. Drs. Fonseca and Findling are authors of an article published in the journal Diabetes Care looking at the CATALYST study: “Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.” This episode is made possible by support from Corcept Therapeutics Inc. Show notes are available at https://www.endocrine.org/podcast/enp110 — for helpful links or to hear more podcast episodes, visit…

People in this episode

Host: Aaron Lohr

Guests: Vivian A. Fonseca, MD, James W. Findling, MD

Topics covered

• hypercortisolism
• type 2 diabetes
• glucose-lowering therapies
• endocrinology
• health care providers

Keywords

• hypercortisolism
• type 2 diabetes
• glucose-lowering therapies
• endocrinology
• mifepristone
• CATALYST study
• Diabetes Care

Sponsors

Corcept Therapeutics Inc.

Mentioned in this episode

Organizations: Endocrine Society, Diabetes Care

Books & works: Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment

More episodes of Endocrine News Podcast

• ENP111: Addressing the Endocrine Workforce Shortage · February 25, 2026 · 30 min
• ENP109: Anti-Obesity Medications (CME credit available) · January 7, 2026 · 13 min
• ENP108: AI and Robotics in Surgery · December 17, 2025 · 10 min
• ENP107: Compounded Obesity Medications · December 3, 2025 · 12 min
• ENP106: Reversing Bariatric Surgery · November 12, 2025 · 12 min
• ENP105: Tirzepatide and Menopause · October 29, 2025 · 19 min